Oncoinvent ASA Announces Successful Completion of Oversubscribed Private Placement to Advance Cancer Treatment Oncoinvent ASA has successfully concluded a private placement, raising NOK 130 million to accelerate the development of their innovative cancer therapy, Radspherin.

Oncoinvent ASA Announces Successful Completion of Oversubscribed Private Placement to Advance Cancer Treatment #Norway #Oslo #Oncoinvent_ASA #Radspherin #Private_Placement